Literature DB >> 9665478

Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor.

L Quintanilla-Martinez1, C Thieblemont, F Fend, S Kumar, M Pinyol, E Campo, E S Jaffe, M Raffeld.   

Abstract

p27Kip1 is a cyclin-dependent kinase inhibitor that regulates the decision to enter S phase or withdraw from the cell cycle. In resting cells, the level of p27Kip1 provides an inhibitory threshold above which G1 cyclin D/E/cyclin-dependent kinases accumulate before activation; however, in cycling cells, p27Kip1 protein is sequestered by high levels of active cyclin D/cyclin-dependent kinase 4 complexes. As a group, the cyclin-dependent kinase inhibitors have been proposed to act as tumor suppressor genes, and several members have been implicated in the pathogenesis of a variety of human cancers. We examined p27Kip1 expression in 116 non-Hodgkin's lymphomas including 50 cases of MCL (40 typical and 10 blastic variants), 21 follicular lymphomas, 20 diffuse large B-cell lymphomas, 16 chronic lymphocytic leukemias, 8 marginal zone B-cell lymphomas, and 1 splenic marginal zone lymphoma, and correlated its expression with that of the proliferation marker Ki67 (MiB1) and with p53. p27Kip1 gene structure was analyzed by Southern blot in the group of MCLs. In all cases of non-Hodgkin's lymphoma other than MCL, p27Kip1 expression was inversely related to the proliferation index as measured by Ki67. In contrast, in typical MCL, p27Kip1 expression was negative in 35 of 40 (88%) cases, irrespective of the proliferative rate (median 15%; range 2 to 90%). Paradoxically, in the blastic variant of MCL, 8 of 10 (80%) cases showed expression of p27Kip1, despite a high proliferation rate (median 60%; range 32 to 100%). However, the staining in most of the cases was less intense than in the reactive T lymphocytes. Deletions of p27Kip1 gene were not found in any of the 25 cases examined. p53 expression was found in 15 of 50 cases of MCL: 7 of 10 (70%) in the blastic variant and 8 of 40 (20%) in the typical MCL (70% vs. 20%, P < 0.0045). These results demonstrate that MCLs, in contrast to other non-Hodgkin's lymphomas and normal lymphoid tissue, fail to correlate p27Kip1 expression with the proliferation rate. This peculiar uncoupling of p27Kip1 protein expression from the proliferation rate may be related to the high levels of cyclin D1 expressed in MCL and is likely to have profound effects on cell cycle regulation and contribute to the pathogenesis of MCL.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9665478      PMCID: PMC1852938          DOI: 10.1016/S0002-9440(10)65558-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  40 in total

Review 1.  Role of the cyclin-dependent kinase inhibitors in the development of cancer.

Authors:  T Hirama; H P Koeffler
Journal:  Blood       Date:  1995-08-01       Impact factor: 22.113

Review 2.  Inhibitors of mammalian G1 cyclin-dependent kinases.

Authors:  C J Sherr; J M Roberts
Journal:  Genes Dev       Date:  1995-05-15       Impact factor: 11.361

3.  Dependence of cyclin E-CDK2 kinase activity on cell anchorage.

Authors:  F Fang; G Orend; N Watanabe; T Hunter; E Ruoslahti
Journal:  Science       Date:  1996-01-26       Impact factor: 47.728

4.  Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies.

Authors:  N Kawamata; R Morosetti; C W Miller; D Park; K S Spirin; T Nakamaki; S Takeuchi; Y Hatta; J Simpson; S Wilcyznski
Journal:  Cancer Res       Date:  1995-06-01       Impact factor: 12.701

5.  Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation.

Authors:  J Y Kato; M Matsuoka; K Polyak; J Massagué; C J Sherr
Journal:  Cell       Date:  1994-11-04       Impact factor: 41.582

Review 6.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors:  N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

7.  p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors.

Authors:  M V Ponce-Castañeda; M H Lee; E Latres; K Polyak; L Lacombe; K Montgomery; S Mathew; K Krauter; J Sheinfeld; J Massague
Journal:  Cancer Res       Date:  1995-03-15       Impact factor: 12.701

8.  Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer.

Authors:  F Bullrich; T K MacLachlan; N Sang; T Druck; M L Veronese; S L Allen; N Chiorazzi; A Koff; K Heubner; C M Croce
Journal:  Cancer Res       Date:  1995-03-15       Impact factor: 12.701

9.  Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias.

Authors:  J A Pietenpol; S K Bohlander; Y Sato; N Papadopoulos; B Liu; C Friedman; B J Trask; J M Roberts; K W Kinzler; J D Rowley
Journal:  Cancer Res       Date:  1995-03-15       Impact factor: 12.701

10.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.

Authors:  M Pagano; S W Tam; A M Theodoras; P Beer-Romero; G Del Sal; V Chau; P R Yew; G F Draetta; M Rolfe
Journal:  Science       Date:  1995-08-04       Impact factor: 47.728

View more
  22 in total

1.  Composite low grade B-cell lymphomas with two immunophenotypically distinct cell populations are true biclonal lymphomas. A molecular analysis using laser capture microdissection.

Authors:  F Fend; L Quintanilla-Martinez; S Kumar; M W Beaty; L Blum; L Sorbara; E S Jaffe; M Raffeld
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

2.  The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.

Authors:  Mohammad Luqman; Sha Klabunde; Karen Lin; Georgios V Georgakis; Anu Cherukuri; Jocelyn Holash; Cheryl Goldbeck; Xiaomei Xu; Edward E Kadel; Sang Hoon Lee; Sharon Lea Aukerman; Bahija Jallal; Natasha Aziz; Wen-Kai Weng; William Wierda; Susan O'Brien; Anas Younes
Journal:  Blood       Date:  2008-05-22       Impact factor: 22.113

3.  Molecular signatures for CCN1, p21 and p27 in progressive mantle cell lymphoma.

Authors:  Afak Rasheed Salman Zaidi; Sadie Dresman; Charlotte Burt; Simon Rule; Lynn McCallum
Journal:  J Cell Commun Signal       Date:  2018-11-21       Impact factor: 5.782

4.  Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events.

Authors:  Leticia Quintanilla-Martinez; Marcus Kremer; Katja Specht; Julia Calzada-Wack; Michaela Nathrath; Robert Schaich; Heinz Höfler; Falko Fend
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

5.  Selective generation of functional somatically mutated IgM+CD27+, but not Ig isotype-switched, memory B cells in X-linked lymphoproliferative disease.

Authors:  Cindy S Ma; Stefania Pittaluga; Danielle T Avery; Nathan J Hare; Irina Maric; Amy D Klion; Kim E Nichols; Stuart G Tangye
Journal:  J Clin Invest       Date:  2006-01-19       Impact factor: 14.808

6.  Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis.

Authors:  Marcia L Taylor; Devinder Sehgal; Mark Raffeld; Harold Obiakor; Cem Akin; Rose G Mage; Dean D Metcalfe
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

7.  Clinicopathologic features of CDK6 translocation-associated B-cell lymphoproliferative disorders.

Authors:  Dong Chen; Mark E Law; Jason D Theis; Jeffrey D Gamez; Lynn B Caron; Julie A Vrana; Ahmet Dogan
Journal:  Am J Surg Pathol       Date:  2009-05       Impact factor: 6.394

8.  Differential expression of IRF8 in subsets of macrophages and dendritic cells and effects of IRF8 deficiency on splenic B cell and macrophage compartments.

Authors:  Chen-Feng Qi; Zhaoyang Li; Mark Raffeld; Hongsheng Wang; Alexander L Kovalchuk; Herbert C Morse
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

9.  Expression of cyclin-dependent kinase inhibitor p27(Kip1) in AIDS-related diffuse large-cell lymphomas is associated with Epstein-Barr virus-encoded latent membrane protein 1.

Authors:  Annunziata Gloghini; Gianluca Gaidano; Luigi M Larocca; Francesco Pierconti; Antonella Cingolani; Luigino Dal Maso; Daniela Capello; Silvia Franceschi; Umberto Tirelli; Massimo Libra; Huifeng Niu; Riccardo Dalla-Favera; Antonino Carbone
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

10.  p27(kip1) and Other Cell-Cycle Protein Expression in Normal and Neoplastic Endocrine Tissues.

Authors:  Lori A. Erickson
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.